Goodpasture's Disease (Anti-GBM)

1. Clinical Overview

Summary

Goodpasture's disease (anti-GBM disease) is a rare but life-threatening autoimmune disorder characterized by circulating antibodies directed against the α3 chain of type IV collagen in the glomerular basement membrane (GBM) and alveolar basement membrane. The disease typically presents as rapidly progressive glomerulonephritis (RPGN) with or without pulmonary hemorrhage, constituting a medical emergency requiring immediate diagnosis and aggressive treatment. Annual incidence is 0.5-1.8 cases per million population, with bimodal age distribution peaking at 20-30 years and 60-70 years. [1,2] The pathognomonic histological feature is linear IgG deposition along the GBM on immunofluorescence microscopy. Without treatment, mortality approaches 90% within months; however, early intervention with plasmapheresis, corticosteroids, and cyclophosphamide achieves remission in 75-90% of cases. [3,4] Prognosis depends critically on renal function at presentation, with dialysis-dependency at diagnosis predicting poor renal recovery.

Key Facts

• Incidence: 0.5-1.8 per million population annually; accounts for 10-20% of RPGN cases. [1,2]
• Age Distribution: Bimodal peaks at 20-30 years (predominantly male) and 60-70 years (equal sex distribution). [5]
• Male:Female Ratio: 6:1 in younger cohort; 1:1 in older cohort. [5]
• Pathology: Autoantibodies to α3(IV)NC1 domain of type IV collagen in GBM and alveolar basement membrane. [6]
• Presentation Patterns: Pulmonary-renal syndrome (60-80%), isolated renal (20-40%), isolated pulmonary (less than 5%). [2,7]
• Double-Positive Disease: 10-40% co-express ANCA antibodies (usually MPO-ANCA), associated with worse prognosis. [8,9]
• Mortality: Historically >90% without treatment; now less than 10% with early aggressive therapy. [3,4]
• Renal Recovery: 95% if treated before creatinine >500 μmol/L; only 8-10% if dialysis-dependent at diagnosis. [10,11]
• Relapse Rate: less than 5% after achieving antibody-negative remission. [3]

Clinical Pearls

Diagnostic Urgency: Anti-GBM disease progresses faster than other RPGN causes. Median time from symptom onset to dialysis-dependency is 3-4 weeks untreated. Every day of delay reduces likelihood of renal recovery by approximately 3%. [10,11]

Smoking is the Dominant Environmental Trigger: 80-95% of patients with pulmonary hemorrhage are current or recent smokers (within 1 year). Smoking increases risk 20-fold by exposing alveolar basement membrane antigens through epithelial injury. [12,13]

The Linear IgG Pattern is Pathognomonic: On renal biopsy immunofluorescence, continuous linear ribbon-like IgG deposition along GBM is diagnostic. This contrasts with granular ("lumpy-bumpy") deposits in immune complex disease and absent/minimal staining in ANCA vasculitis. [14]

Anti-GBM Antibody Testing Has Excellent Diagnostic Performance: Modern chemiluminescence and ELISA assays have 95-100% sensitivity and 97-100% specificity for anti-GBM antibodies. [15,16] However, rare seronegative cases exist, making renal biopsy mandatory for diagnosis confirmation.

Plasmapheresis Must Begin Within 48 Hours: Immediate plasma exchange is critical—antibodies continue causing irreversible glomerular injury until removed. Standard immunosuppression alone is insufficient to prevent ESRD. [3,17]

Why This Matters Clinically

• Reversibility Window: Anti-GBM disease is one of few causes of RPGN where early intervention can completely preserve renal function, but this window closes rapidly (typically 7-14 days from symptom onset). [10,11]
• High Untreated Mortality: Without plasmapheresis and immunosuppression, 1-year mortality exceeds 50% from pulmonary hemorrhage or uremia. [3,4]
• Excellent Remission Rates: 75-90% achieve antibody-negative remission with standard therapy, and relapse is rare (less than 5%), offering excellent long-term prognosis for early-treated patients. [3,18]
• Differential Diagnosis Imperative: Distinguishing anti-GBM from ANCA vasculitis and lupus nephritis is critical as treatment urgency, prognosis, and monitoring differ substantially.
• Transplant Candidacy: Patients achieving antibody clearance have excellent renal transplant outcomes (>90% 5-year graft survival) with minimal recurrence risk (less than 3%). [19]

---

2. Epidemiology

Global Burden and Demographics

Incidence and Prevalence:

• Annual incidence: 0.5-1.8 per million population (0.9 per million in European registries). [1,2]
• Accounts for 10-20% of all RPGN cases; 1-5% of glomerulonephritis biopsies. [20]
• Point prevalence: ~1-2 per million.
• Slight increase in incidence over past 2 decades, likely due to improved diagnostic testing. [1]

Age and Sex Distribution:

• Bimodal age distribution: [5]
  • "Young cohort: Peak at 20-30 years, male:female ratio 6:1, higher rate of pulmonary hemorrhage (80-90%)"
  • "Older cohort: Peak at 60-70 years, male:female ratio ~1:1, more isolated renal disease (40-60%)"
• Rare in children (less than 5% of cases); pediatric cases often double-positive (anti-GBM + ANCA). [21]

Geographic and Ethnic Variation:

• Higher incidence in Northern European and Caucasian populations. [1,2]
• Lower incidence in African, Asian, and Hispanic populations.
• Seasonal variation reported with winter/spring predominance (possibly linked to respiratory infections). [12]

Risk Factors and Associations

Clinical Presentation Patterns

Distribution by Organ Involvement: [2,7]

• Pulmonary-Renal Syndrome: 60-80% (most common, typically younger males, smokers)
• Isolated Renal Disease: 20-40% (more common in older patients, non-smokers)
• Isolated Pulmonary Disease: less than 5% (rare, often proceeds to renal involvement)

Sequential Presentation:

• Pulmonary symptoms typically precede renal manifestations by days to weeks in 40-60% of cases. [7]
• Renal-first presentation in 30-40%.
• Simultaneous onset in 10-20%.

Natural History and Outcomes

Untreated Disease:

• Median time to ESRD: 3-4 weeks from symptom onset. [10]
• 1-year mortality: 50-90% (death from pulmonary hemorrhage or uremia). [3,4]
• 5-year mortality: >90%.

Treated Disease:

• Patient survival: 85-95% at 1 year; 75-85% at 5 years (deaths primarily from treatment complications or comorbidities). [3,18]
• Renal survival: 40-60% avoid long-term dialysis with early treatment. [10,11]
• Dialysis-independent at 1 year: 40-60% overall; 95% if treated before dialysis-dependency. [10,11]

Predictors of Renal Survival: [10,11,23]

• Strong Positive Predictors: Serum creatinine less than 500 μmol/L (5.7 mg/dL) at diagnosis; oliguria absent; plasma exchange initiated within 2 weeks; less than 50% crescents on biopsy
• Strong Negative Predictors: Dialysis-dependency at presentation (only 8-10% renal recovery); 100% crescents on biopsy; delayed treatment >3 weeks

---

3. Pathophysiology

Molecular Mechanisms

The Target Antigen: Type IV collagen is the primary structural component of basement membranes throughout the body. The α3(IV), α4(IV), and α5(IV) chains are expressed specifically in glomerular and alveolar basement membranes. The pathogenic epitope is the non-collagenous domain (NC1) of the α3(IV) chain, termed the Goodpasture antigen. [6,24]

• α3(IV)NC1 domain: Contains conformational epitopes EA and EB that are cryptic (hidden) under normal conditions.
• Epitope exposure: Smoking, infection, hydrocarbons, or fluid overload disrupt the basement membrane quaternary structure, exposing previously hidden epitopes.
• Autoantibody formation: B cells produce IgG1 and IgG3 antibodies (complement-fixing subclasses) against exposed epitopes.

Pathogenic Sequence

Step 1: Environmental Trigger and Antigen Exposure [12,13]

• Smoking causes alveolar epithelial injury, oxidative stress, and increased basement membrane permeability.
• Inhaled toxins (hydrocarbons, cocaine) directly damage alveolar lining.
• Respiratory infections induce epithelial injury and may trigger molecular mimicry.
• Fluid overload increases capillary pressure, exposing cryptic epitopes.

Step 2: Breakdown of Immune Tolerance [22,24]

• Loss of regulatory T-cell control over self-reactive B cells.
• Genetic predisposition (HLA-DR15 association) alters antigen presentation and T-cell regulation.
• B-cell activation and production of high-affinity IgG antibodies against α3(IV)NC1.

Step 3: Antibody Binding and Complement Activation [6,24]

• Circulating anti-GBM antibodies bind to α3(IV)NC1 domains in glomerular and alveolar basement membranes.
• Linear continuous ribbon-like IgG deposition along basement membrane (pathognomonic feature).
• Classical complement pathway activation via IgG Fc regions.
• C3a and C5a generation recruits neutrophils and macrophages.

Step 4: Inflammatory Injury [6,14]

• Neutrophil degranulation releases proteases (elastase, myeloperoxidase), reactive oxygen species, and metalloproteinases.
• Macrophage activation produces pro-inflammatory cytokines (TNF-α, IL-1, IL-6).
• Direct podocyte injury causes foot process effacement and proteinuria.
• Basement membrane disruption allows inflammatory cell migration into Bowman's space.
• Fibrin deposition and crescent formation (proliferation of parietal epithelial cells and infiltrating macrophages).

Step 5: Glomerular Destruction and Fibrosis [14]

• Progressive crescent formation compresses glomerular capillaries, causing ischemia.
• Tubular atrophy and interstitial fibrosis develop secondary to glomerular failure.
• Irreversible scarring occurs if treatment delayed beyond 2-3 weeks.

Step 6: Pulmonary Hemorrhage [7,13]

• Anti-GBM antibodies bind alveolar basement membrane (same α3(IV)NC1 epitope).
• Complement activation and neutrophil infiltration disrupt alveolar-capillary barrier.
• Red blood cells extravasate into alveolar spaces.
• Hemosiderin-laden macrophages appear within 48-72 hours.
• Diffuse alveolar hemorrhage (DAH) manifests as hemoptysis, dyspnea, hypoxemia, and alveolar infiltrates.

Immunopathogenic Subtypes

Classic Anti-GBM Disease (60-90%): [2,6]

• Isolated anti-GBM antibodies.
• Linear IgG (and C3) on immunofluorescence.
• Necrotizing crescentic glomerulonephritis on histology.
• Standard treatment response.

Double-Positive Disease (Anti-GBM + ANCA) (10-40%): [8,9]

• Concurrent anti-GBM and ANCA (usually MPO-ANCA).
• Mixed features: crescentic GN with linear IgG plus pauci-immune features or vasculitic changes.
• More frequent granulomatous inflammation, pulmonary nodules, upper respiratory involvement.
• Worse renal prognosis and higher relapse rate (10-20% vs. less than 5% for isolated anti-GBM).
• May require prolonged immunosuppression (12-18 months vs. 6-9 months).

Atypical Anti-GBM Disease (Rare): [25]

• Seronegative anti-GBM disease: linear IgG on biopsy but negative serum antibodies (1-5% of cases; antibodies may be low-affinity or rapidly cleared).
• IgA anti-GBM disease: linear IgA instead of IgG (case reports only).
• Alport post-transplant anti-GBM: patients with Alport syndrome (hereditary absence of α3/α4/α5 chains) develop anti-GBM antibodies after renal transplant exposure to "foreign" normal GBM.

Genetic and Environmental Interactions

HLA Associations: [22]

• HLA-DR15 (DRB1*1501): Strongest association, OR 3-8; found in 70-90% of patients vs. 25-35% in general population.
• HLA-DR4: Secondary association.
• HLA-B7: Reported in some cohorts.
• Mechanism: HLA molecules influence antigen presentation and T-cell repertoire selection.

Gene-Environment Interaction: [12,13,22]

• HLA-DR15 carriers who smoke have 100-fold increased risk compared to non-smoking, non-HLA-DR15 individuals.
• Environmental triggers are necessary but not sufficient; genetic susceptibility determines who develops disease.

---

4. Clinical Presentation

Classic Triad (Pulmonary-Renal Syndrome)

1. Hemoptysis (60-80% of cases): [2,7]

   • Ranges from blood-streaked sputum to massive life-threatening hemorrhage (>500 mL/24h).
   • Characteristically precedes renal symptoms by days to weeks.
   • Severity correlates with smoking status and alveolar-capillary permeability.

2. Dyspnea and Hypoxemia (60-80%): [7]

   • Progressive shortness of breath from diffuse alveolar hemorrhage.
   • Hypoxemic respiratory failure in 20-40% (PaO2 less than 60 mmHg on room air).
   • Paradoxical improvement in gas exchange initially due to intra-alveolar hemoglobin binding CO (increased DLCO on pulmonary function testing).

3. Rapidly Progressive Glomerulonephritis (90-100%): [2,14]

   • Rapid decline in renal function over days to weeks.
   • Oliguria (urine output less than 400 mL/24h) in 50-70%.
   • Anuria (less than 100 mL/24h) in 10-20%.
   • Median time from normal creatinine to dialysis-dependency: 3-4 weeks untreated. [10]

Symptoms by Frequency

Examination Findings

Vital Signs:

• Hypertension: 30-50% (volume overload and acute kidney injury).
• Tachycardia: Common (anemia, hypoxemia, distress).
• Tachypnea: 60-80% (hypoxemia, metabolic acidosis).
• Fever: 30-50% (low-grade, non-infectious).
• Hypotension: Rare unless massive hemorrhage or sepsis.

Respiratory Examination:

• Crackles (rales): Bilateral, diffuse (alveolar hemorrhage or pulmonary edema).
• Decreased breath sounds: If pleural effusion (uncommon).
• Cyanosis: Severe hypoxemia.
• Increased work of breathing: Accessory muscle use, nasal flaring.

Cardiovascular and Renal:

• Peripheral edema: Pitting edema of ankles, legs, sacrum.
• Elevated JVP: Fluid overload.
• Pericardial friction rub: Uremic pericarditis (if advanced uremia).
• Pallor: Severe anemia.

General Examination:

• Pallor: Profound (Hb often 60-90 g/L).
• No rash (contrasts with ANCA vasculitis, SLE).
• No lymphadenopathy or organomegaly (unless infection complication).

Atypical Presentations

Isolated Renal Disease (20-40%): [2,7]

• RPGN without pulmonary symptoms.
• More common in older patients and non-smokers.
• May have subclinical pulmonary hemorrhage (CT infiltrates without hemoptysis).
• Better short-term prognosis (no life-threatening bleeding) but same renal outcomes.

Isolated Pulmonary Disease (less than 5%): [7]

• Diffuse alveolar hemorrhage without renal involvement at presentation.
• Renal disease typically develops within weeks to months (serial monitoring essential).
• Rare cases remain pulmonary-limited indefinitely.

Subacute/Chronic Presentation (10-20%):

• Gradual decline over weeks to months rather than days.
• May present with established chronic kidney disease (CKD) and chronic anemia.
• Worse prognosis due to delayed diagnosis and irreversible fibrosis.

Double-Positive Disease (10-40%): [8,9]

• Concurrent anti-GBM and ANCA antibodies.
• More systemic vasculitic features: skin rash, peripheral neuropathy, upper respiratory involvement (sinusitis, epistaxis), pulmonary nodules.
• Granulomatous inflammation on biopsy (overlapping with granulomatosis with polyangiitis).
• Higher relapse rate (10-20%); requires prolonged immunosuppression.

Red Flags for Life-Threatening Disease

1. Massive Pulmonary Hemorrhage (5-10% of cases):

   • >500 mL hemoptysis in 24 hours.
   • Requires ICU admission, intubation, high-PEEP ventilation.
   • May need extracorporeal membrane oxygenation (ECMO) if refractory hypoxemia.

2. Severe Acute Kidney Injury:

   • Anuria or creatinine >700 μmol/L (8 mg/dL): predicts permanent dialysis dependency.
   • Hyperkalemia >6.5 mmol/L: risk of cardiac arrhythmia.
   • Severe metabolic acidosis (pH less than 7.2): requires urgent dialysis.

3. Respiratory Failure:

   • PaO2 less than 60 mmHg on high-flow oxygen (FiO2 >0.6).
   • PaCO2 retention (>50 mmHg) suggesting respiratory muscle fatigue.

4. Septic Complications:

   • Pulmonary hemorrhage may become secondarily infected (pneumonia).
   • Central venous catheter infections (plasmapheresis catheters).
   • Immunosuppression-related opportunistic infections.

---

5. Clinical Examination

Systematic Approach

Initial Assessment (ABCDE):

• Airway: Patent; assess for blood/clots if hemoptysis.
• Breathing: Respiratory rate, oxygen saturation, work of breathing, auscultation.
• Circulation: Blood pressure, heart rate, JVP, peripheral perfusion, edema.
• Disability: Conscious level (uremic encephalopathy if advanced).
• Exposure: Skin examination (vasculitic rash suggests alternative/additional diagnosis).

Detailed Respiratory Examination

Inspection:

• Respiratory rate (typically 20-30/min).
• Accessory muscle use.
• Cyanosis (central: tongue, lips).
• Hemoptysis: assess volume and character (frothy pink suggests pulmonary edema; frank blood suggests hemorrhage).

Palpation:

• Trachea central.
• Chest expansion symmetrical (reduced if bilateral disease).
• Tactile fremitus may be increased over areas of consolidation/hemorrhage.

Percussion:

• Dullness over areas of alveolar hemorrhage or consolidation.
• Stony dullness if pleural effusion (uncommon).

Auscultation:

• Crackles (fine, bilateral, diffuse) from alveolar hemorrhage or pulmonary edema.
• Bronchial breathing over consolidated areas.
• Reduced air entry if pleural effusion.

Renal and Cardiovascular Examination

Fluid Status Assessment:

• JVP: Elevated if fluid overload.
• Peripheral edema: Pitting edema (ankles, legs, sacrum).
• Pulmonary edema: Crackles, orthopnea.
• Hypertension: Systolic BP often 140-180 mmHg.

Cardiovascular Examination:

• Tachycardia.
• Heart sounds: S3 gallop if fluid overload.
• Pericardial friction rub: Uremic pericarditis (late finding).

Abdominal Examination:

• Kidneys: Usually non-palpable (normal size in acute disease).
• No organomegaly unless complication.
• No peritonism.

Neurological Examination

Assess for Uremic Encephalopathy:

• Confusion, lethargy, asterixis (flapping tremor).
• Seizures (rare, severe uremia or hypertensive encephalopathy).

Assess for Vasculitic Neuropathy (if ANCA-positive):

• Mononeuritis multiplex.
• Peripheral sensory or motor deficits.

General Examination

Skin:

• Pallor: Severe anemia (conjunctival, palmar).
• No vasculitic rash (purpura, necrotic lesions) in classic anti-GBM (suggests ANCA or alternative diagnosis).
• Petechiae/ecchymoses: Uremic platelet dysfunction or thrombocytopenia.

ENT Examination (if ANCA-positive):

• Nasal septal perforation, crusting, epistaxis (granulomatosis with polyangiitis features).

---

6. Investigations

Essential First-Line Investigations

1. Anti-GBM Antibody Testing [15,16]

Serum Anti-GBM Antibodies:

• Method: Enzyme-linked immunosorbent assay (ELISA) or chemiluminescence immunoassay (CIA) targeting recombinant α3(IV)NC1 antigen.
• Sensitivity: 95-100% (CIA/ELISA).
• Specificity: 97-100%.
• Turnaround Time: 24-48 hours in specialized laboratories; point-of-care tests under development.
• Quantification: Antibody titer does not correlate precisely with disease severity but useful for monitoring treatment response.
• False Negatives: 1-5% of cases are seronegative (low-affinity antibodies, rapid clearance, or technical limitations); renal biopsy remains gold standard. [25]

Interpretation:

• Positive result in appropriate clinical context (RPGN ± pulmonary hemorrhage) is diagnostic.
• Negative result does NOT exclude disease; proceed to urgent renal biopsy if clinical suspicion high.

2. Renal Biopsy (Gold Standard) [14,25]

Indications:

• All suspected cases, even if anti-GBM antibodies positive (confirm diagnosis, assess severity, exclude alternative/concurrent diagnoses).
• Mandatory if seronegative with clinical suspicion.

Timing:

• Urgent: within 24-48 hours of presentation.
• Do NOT delay for correction of mild coagulopathy or controlled hypertension.
• Can be performed safely on dialysis patients.

Light Microscopy Findings:

• Crescentic glomerulonephritis: >50% of glomeruli with cellular or fibrocellular crescents (proliferation of parietal epithelial cells in Bowman's space).
• Glomerular necrosis with fibrinoid necrosis and capillary loop rupture.
• Tubulointerstitial inflammation and acute tubular injury.
• Vascular changes absent (distinguishes from vasculitis).

Immunofluorescence (Pathognomonic):

• Linear IgG deposition along glomerular basement membrane: continuous ribbon-like staining (intensity 2-3+ on 0-3+ scale).
• C3 deposition often present (linear pattern).
• Absence of immune complex deposits (distinguishes from lupus, IgA nephropathy, post-infectious GN).
• Distinguishes from pauci-immune GN (ANCA vasculitis): minimal/absent Ig staining.

Electron Microscopy:

• No immune complex deposits (confirms pauci-immune nature).
• GBM may appear normal or show irregular contours from inflammatory injury.
• Foot process effacement.

Prognostic Histological Features: [10,11,23]

• Percentage of crescents: >50% crescents predicts poor renal recovery; 100% crescents associated with only 5-10% dialysis-free survival.
• Fibrous vs. cellular crescents: Fibrous crescents indicate chronicity and irreversibility.
• Glomerulosclerosis: Percentage of globally sclerosed glomeruli.
• Tubulointerstitial fibrosis: Extent of chronic scarring.

3. Urinalysis and Urine Microscopy

Findings:

• Hematuria: Universal (90-100%); typically >100 RBCs/hpf.
• Dysmorphic RBCs: Glomerular origin (phase-contrast microscopy shows >40% dysmorphic forms).
• Red blood cell casts: Pathognomonic for glomerulonephritis; present in 50-80%.
• Proteinuria: Typically 1-3 g/24h (nephritic range); nephrotic-range proteinuria (>3.5 g/24h) in 10-20%.
• Leucocyturia: Sterile pyuria from glomerular inflammation.

4. Renal Function Tests

Serum Creatinine and eGFR:

• Creatinine typically >300 μmol/L (3.4 mg/dL) at presentation; often >500 μmol/L (5.7 mg/dL).
• Rapid rise: doubling of creatinine within 1-2 weeks.
• eGFR often less than 15 mL/min/1.73m² at diagnosis.

Blood Urea Nitrogen (BUN):

• Elevated proportionate to creatinine; BUN:creatinine ratio often >20:1 (prerenal component from hypovolemia or bleeding).

Electrolytes:

• Hyperkalemia: Common (K⁺ 5-7 mmol/L); requires urgent management if >6 mmol/L.
• Metabolic acidosis: Low bicarbonate (less than 15 mmol/L); high anion gap.
• Hypocalcemia, hyperphosphatemia: Advanced kidney injury.

5. Complete Blood Count (CBC)

Anemia:

• Normocytic, normochromic anemia: Hb often 60-90 g/L.
• Multifactorial: pulmonary/GI hemorrhage, hemolysis (microangiopathic), bone marrow suppression (uremia), hemodilution.
• Iron deficiency if chronic occult pulmonary bleeding.

Leukocytosis:

• Neutrophil-predominant leukocytosis (12,000-20,000/μL) from inflammation.

Thrombocytopenia:

• Mild (100,000-150,000/μL) in some cases; severe thrombocytopenia suggests alternative diagnosis (TTP, HUS).

6. Inflammatory Markers

ESR and CRP:

• Elevated: ESR often 40-100 mm/h; CRP 50-200 mg/L.
• Reflects systemic inflammation.

Complement Levels:

• Normal C3 and C4: Distinguishes from lupus nephritis and post-infectious GN (which have low complement).
• Exception: Slight C3 consumption may occur due to classical pathway activation.

7. Chest Imaging

Chest X-ray: [7]

• Bilateral alveolar infiltrates: "Bat-wing" or perihilar distribution; patchy or diffuse.
• Migratory infiltrates (change location over 24-48 hours as bleeding shifts).
• Normal cardiac silhouette (distinguishes from cardiogenic pulmonary edema).
• Pleural effusions uncommon (10-20%).

High-Resolution CT Chest:

• Ground-glass opacities: Acute alveolar hemorrhage.
• Consolidation: Confluent areas of hemorrhage.
• Crazy-paving pattern: Ground-glass with septal thickening.
• Centrilobular nodules: Uncommon (suggests alternative diagnosis like vasculitis or infection).
• No cavitation, masses, or lymphadenopathy (if present, consider ANCA vasculitis or malignancy).

8. Bronchoscopy and Bronchoalveolar Lavage (BAL) [7]

Indications:

• Confirm diffuse alveolar hemorrhage.
• Exclude infection (secondary pneumonia).
• When pulmonary infiltrates present but hemoptysis absent (occult hemorrhage).

Findings:

• Progressively bloody return: Sequential aliquots become more hemorrhagic (not dilutional).
• Hemosiderin-laden macrophages: >20% on Prussian blue stain (appear 48-72 hours after bleeding).
• Elevated RBC count in BAL fluid (>5% of total cells).
• Negative cultures (sterile hemorrhage).

Contraindications:

• Severe hypoxemia (PaO2 less than 50 mmHg) without mechanical ventilation.
• Coagulopathy or thrombocytopenia (relative contraindication).

Advanced/Ancillary Investigations

9. ANCA Testing [8,9]

Indications:

• All patients with anti-GBM disease (10-40% are double-positive).

Method:

• Immunofluorescence (IF): c-ANCA (cytoplasmic) or p-ANCA (perinuclear) pattern.
• Antigen-specific ELISA: anti-PR3 (proteinase 3) or anti-MPO (myeloperoxidase).

Findings in Double-Positive Disease:

• Concurrent anti-GBM and MPO-ANCA (most common): 80% of double-positive cases.
• Concurrent anti-GBM and PR3-ANCA: 20% of double-positive cases.

Clinical Significance:

• Double-positive disease has worse renal prognosis, higher relapse rate (10-20%), and may require prolonged immunosuppression.

10. Autoimmune Serology Panel

ANA, anti-dsDNA, Complement (C3, C4):

• Exclude systemic lupus erythematosus (SLE): ANA often positive in SLE; anti-dsDNA specific; low C3/C4.

Anti-Phospholipase A2 Receptor (PLA2R), Anti-Thrombospondin Type-1 Domain-Containing 7A (THSD7A):

• Exclude membranous nephropathy (different histology but important differential).

Cryoglobulins, Hepatitis B/C Serology:

• Exclude cryoglobulinemic vasculitis or hepatitis-associated GN.

11. HLA Typing [22]

Clinical Use:

• Research tool; not routinely performed.
• HLA-DR15 (DRB1*1501) present in 70-90% of anti-GBM patients.
• May inform genetic counseling for family members.

12. Echocardiography

Indications:

• Assess cardiac function before plasmapheresis and fluid management.
• Exclude pericardial effusion (uremic pericarditis).
• Assess for pulmonary hypertension (if chronic pulmonary disease).

13. Renal Ultrasound

Findings:

• Normal-sized kidneys: Confirms acute process (distinguishes from chronic kidney disease).
• Normal echogenicity or mildly increased.
• No hydronephrosis.
• Doppler: Patent renal vessels (exclude renal vein thrombosis).

---

7. Diagnostic Algorithm

Clinical Suspicion

Triggers for Considering Anti-GBM Disease:

1. Pulmonary-renal syndrome: Hemoptysis + AKI.
2. Rapidly progressive glomerulonephritis: Creatinine doubling over days to weeks + active urinary sediment (RBC casts).
3. Unexplained diffuse alveolar hemorrhage in young adults or smokers.
4. Acute kidney injury with hematuria and proteinuria without alternative explanation.

Diagnostic Pathway

SUSPECTED ANTI-GBM DISEASE
         ↓
┌─────────────────────────────────────────────┐
│      IMMEDIATE ACTIONS (Within 4 hours)     │
│  1. Serum anti-GBM antibodies (ELISA/CIA)   │
│  2. ANCA serology (c-ANCA/p-ANCA, PR3, MPO) │
│  3. Urinalysis + microscopy (RBC casts)     │
│  4. Renal function (creatinine, eGFR, K⁺)   │
│  5. CBC (Hb, platelets)                     │
│  6. Chest X-ray or CT chest                 │
│  7. Autoimmune panel (ANA, complement)      │
│  8. Blood gas (assess acidosis, hypoxemia)  │
└─────────────────────────────────────────────┘
         ↓
┌─────────────────────────────────────────────┐
│      URGENT RENAL BIOPSY (Within 24-48h)   │
│  - DO NOT wait for antibody results         │
│  - Light microscopy: crescentic GN          │
│  - Immunofluorescence: LINEAR IgG (diagnostic) │
│  - Assess % crescents (prognosis)           │
└─────────────────────────────────────────────┘
         ↓
┌─────────────────────────────────────────────┐
│           DIAGNOSTIC CONFIRMATION           │
│  Anti-GBM Antibody (+) AND/OR               │
│  Linear IgG on renal biopsy IF              │
│  + Clinical syndrome (RPGN ± pulmonary Hgb) │
└─────────────────────────────────────────────┘
         ↓
┌─────────────────────────────────────────────┐
│      SUBTYPE CLASSIFICATION                 │
│  - Classic anti-GBM (ANCA-negative)         │
│  - Double-positive (anti-GBM + ANCA)        │
│  - Atypical (seronegative, IgA variant)     │
└─────────────────────────────────────────────┘
         ↓
START TREATMENT IMMEDIATELY
(DO NOT await biopsy if antibody positive + clinical syndrome)

Differential Diagnosis

---

8. Management

Principles of Treatment

Anti-GBM disease requires immediate, aggressive, triple therapy:

1. Plasmapheresis (Plasma Exchange): Removes circulating pathogenic antibodies.
2. High-Dose Corticosteroids: Suppress inflammation and antibody production.
3. Cyclophosphamide: Prevents further antibody synthesis by B cells.

Treatment must begin within 24-48 hours of diagnosis to prevent irreversible renal fibrosis. [3,4,17]

Management Algorithm

CONFIRMED ANTI-GBM DISEASE
         ↓
┌─────────────────────────────────────────────┐
│      IMMEDIATE STABILIZATION (Within 1h)    │
│  - High-flow oxygen (target SpO₂ >92%)      │
│  - IV access (large-bore ×2)                │
│  - Central venous catheter (plasmapheresis) │
│  - Urgent nephrology + pulmonology consults │
│  - ICU admission if hypoxemia or AKI severe │
│  - Urgent dialysis if: K⁺ >6.5, pH less than 7.2,    │
│    pulmonary edema, uremia symptoms         │
└─────────────────────────────────────────────┘
         ↓
┌─────────────────────────────────────────────┐
│      PLASMAPHERESIS (Start within 24h)      │
│  - Daily for 14 days, then alternate days   │
│  - 60 mL/kg (4-5 L) plasma exchange/session │
│  - Replace with 5% albumin or FFP           │
│  - Target: anti-GBM antibody undetectable   │
│  - Central line: tunneled, non-cuffed       │
└─────────────────────────────────────────────┘
         ↓
┌─────────────────────────────────────────────┐
│      IMMUNOSUPPRESSION (Start Day 1)        │
│  - Methylprednisolone 1g IV daily × 3 days  │
│  - Then prednisolone 1 mg/kg PO daily       │
│  - Cyclophosphamide 2 mg/kg PO daily OR     │
│    500-750 mg/m² IV monthly (if dialysis)   │
└─────────────────────────────────────────────┘
         ↓
┌─────────────────────────────────────────────┐
│      SUPPORTIVE CARE                        │
│  - Transfusion (target Hb >70-80 g/L)       │
│  - Iron supplementation                     │
│  - EPO if anemia persists                   │
│  - Prophylaxis: PCP (TMP-SMX), PPI, calcium/VitD │
│  - Dialysis as needed (HD or PD)            │
│  - Smoking cessation counseling             │
└─────────────────────────────────────────────┘
         ↓
┌─────────────────────────────────────────────┐
│      MONITORING (Weekly initially)          │
│  - Anti-GBM antibody levels                 │
│  - Renal function (creatinine, eGFR)        │
│  - CBC, platelets, WBC (cytopenias)         │
│  - Urinalysis (hematuria, proteinuria)      │
│  - Infection surveillance                   │
└─────────────────────────────────────────────┘
         ↓
┌─────────────────────────────────────────────┐
│      REMISSION CRITERIA (3-6 months)        │
│  - Anti-GBM antibody negative × 2 tests     │
│  - Stable renal function                    │
│  - No active pulmonary hemorrhage           │
│  - Taper steroids over 6-12 months          │
│  - Stop cyclophosphamide at 3-6 months      │
└─────────────────────────────────────────────┘

Plasmapheresis (Therapeutic Plasma Exchange) [3,17]

Indications:

• All patients with anti-GBM disease and detectable circulating antibodies.
• Even dialysis-dependent patients (10% renal recovery possible; prevents pulmonary hemorrhage). [10,11]

Regimen: [3,17]

• Frequency: Daily sessions for 14 days, then alternate-day for additional 14 days (total 21 sessions over 4-5 weeks).
• Volume: 60 mL/kg body weight (approximately 4-5 liters per session; ~1-1.5 plasma volumes).
• Replacement Fluid:
  • 5% albumin preferred (lower infection/allergy risk).
  • Fresh frozen plasma (FFP) if coagulopathy or active bleeding (contains clotting factors).
• Anticoagulation: Citrate or heparin to prevent clotting in extracorporeal circuit.
• Central Venous Access: Non-tunneled femoral or internal jugular catheter (large-bore, dual-lumen).

Efficacy:

• Reduces anti-GBM antibody titers by 50-70% per session. [3]
• Typically undetectable after 10-14 sessions.
• Renal recovery: 95% if started before dialysis-dependency; 8-10% if dialysis-dependent. [10,11]

Monitoring During Plasmapheresis:

• Coagulation: PT, APTT, fibrinogen (plasmapheresis removes clotting factors; replace with FFP if bleeding).
• Electrolytes: Calcium (citrate binds calcium, causing hypocalcemia; supplement calcium gluconate).
• Infection: Catheter-related bloodstream infection (CRBSI) risk 5-15%; strict aseptic technique.
• Hemodynamics: Hypotension during procedure (fluid shifts); pre-treat with IV saline.

Complications:

• Hypocalcemia (citrate toxicity): perioral numbness, paresthesias, tetany, arrhythmias (treat with IV calcium).
• Catheter-related: infection (5-15%), thrombosis (5-10%), bleeding (2-5%).
• Allergic reactions to FFP (urticaria, anaphylaxis): rare with albumin.
• Hypotension: 10-20% of sessions.

Discontinuation Criteria:

• Anti-GBM antibody undetectable for 2 consecutive measurements (1 week apart).
• Improvement in renal function (creatinine decline >20%).
• No further pulmonary hemorrhage.
• Typically 3-4 weeks of therapy.

Corticosteroids [3,4,17]

Induction (High-Dose Pulse):

• Methylprednisolone: 1000 mg IV daily for 3 days (or 500 mg IV daily for 3-5 days).
• Start immediately at diagnosis (do NOT wait for plasmapheresis catheter).
• Mechanism: Rapid anti-inflammatory effect, suppresses T-cell and B-cell activation.

Maintenance:

• Prednisolone: 1 mg/kg PO daily (maximum 60-80 mg/day) after IV pulse.
• Continue for 3-6 months, then taper.

Tapering Schedule (Standard):

• Weeks 1-4: 60 mg daily.
• Weeks 5-8: 40 mg daily.
• Weeks 9-12: 30 mg daily.
• Months 4-6: 20 mg daily.
• Months 7-9: 10 mg daily, then 5 mg daily.
• Months 10-12: Discontinue (if in remission).

Adjust for:

• Weight less than 50 kg: lower dose (0.75 mg/kg).
• Diabetes: tighter glucose control, consider insulin.
• Infection: hold or reduce dose.

Adverse Effects:

• Hyperglycemia (50-70%): monitor blood glucose; initiate insulin if needed.
• Hypertension (30-50%): may require antihypertensives.
• Gastrointestinal: peptic ulcer (5-10%); use proton pump inhibitor (PPI) prophylaxis.
• Infection risk: 20-40% (pneumonia, opportunistic infections).
• Osteoporosis: long-term risk; calcium/vitamin D supplementation, bisphosphonates if high-risk.
• Psychiatric: mood changes, insomnia, psychosis (5-10%).
• Weight gain, cushingoid features, myopathy.

Cyclophosphamide [3,4,17]

Regimen:

• Oral: 2 mg/kg/day PO (round to nearest 50 mg; typical dose 100-200 mg/day).
  • "Dose adjustment: Reduce for renal impairment (eGFR less than 30: 1.5 mg/kg/day; dialysis: 1 mg/kg/day)."
  • Administer in morning with high fluid intake (reduce bladder toxicity).
• Intravenous (Alternative): 500-750 mg/m² IV monthly for 6 months (if dialysis-dependent or concerns about oral adherence).

Duration:

• 3-6 months (stop when anti-GBM antibody negative for 2-3 months and remission achieved).
• Longer duration (12-18 months) for double-positive disease (anti-GBM + ANCA). [8,9]

Mechanism:

• Alkylating agent; cross-links DNA, inhibits B-cell and T-cell proliferation.
• Prevents further anti-GBM antibody production.

Monitoring:

• Weekly CBC: Watch for leukopenia (WBC less than 3,000/μL), lymphopenia (less than 500/μL), thrombocytopenia.
  • Hold if WBC less than 3,000 or neutrophils less than 1,000; restart at reduced dose when recovered.
• Urinalysis: Monitor for hemorrhagic cystitis (microscopic hematuria).
• Liver function tests: Monitor transaminases.

Adverse Effects:

• Myelosuppression (30-50%): Leukopenia, thrombocytopenia, anemia; increased infection risk.
• Hemorrhagic cystitis (5-15%): Bladder inflammation/bleeding; acrolein metabolite causes urothelial injury.
  • "Prevention: High fluid intake (>3 L/day), morning dosing, mesna (if IV high-dose)."
• Gonadal toxicity (30-90%): Dose- and age-dependent; infertility, premature ovarian failure, azoospermia.
  • Counsel on fertility preservation (sperm banking, oocyte cryopreservation) before treatment.
• Malignancy (long-term): Bladder cancer (5-10% at 10-20 years), lymphoma, leukemia.
• Infection: Opportunistic infections (Pneumocystis jirovecii pneumonia); use TMP-SMX prophylaxis.
• Alopecia (partial).
• Nausea/vomiting: Antiemetics (ondansetron).

Alternatives (if cyclophosphamide contraindicated):

• Rituximab (anti-CD20 monoclonal antibody): 375 mg/m² IV weekly × 4 doses or 1000 mg IV × 2 doses (2 weeks apart).
  • Emerging evidence in anti-GBM disease; case series show efficacy. [26]
  • Consider if cyclophosphamide contraindicated (active malignancy, severe cytopenias, pregnancy).
• Mycophenolate mofetil (MMF): 1000-1500 mg PO twice daily (less potent; limited data in anti-GBM).

Supportive Care

1. Renal Replacement Therapy (Dialysis):

• Indications: Severe AKI with uremia symptoms, hyperkalemia (K⁺ >6.5 mmol/L refractory to medical therapy), metabolic acidosis (pH less than 7.2), fluid overload refractory to diuretics.
• Modality:
  • "Hemodialysis (HD): Preferred acutely; coordinate with plasmapheresis (can perform sequentially or use same catheter)."
  • "Peritoneal dialysis (PD): Option for stable patients preferring home therapy."
• Duration: May be temporary (renal recovery in 40-60% of early-treated patients) or permanent (ESRD in 40-60%). [10,11]

2. Blood Transfusion:

• Indications: Symptomatic anemia (dyspnea, fatigue, chest pain) or Hb less than 70 g/L.
• Target: Hb >70-80 g/L.
• Avoid over-transfusion (increases blood volume, exacerbates pulmonary edema).
• Iron supplementation: Oral (ferrous sulfate 325 mg TID) or IV (iron sucrose, ferric carboxymaltose) if iron-deficient from chronic bleeding.

3. Erythropoiesis-Stimulating Agents (ESA):

• Recombinant human erythropoietin (EPO): 50-100 units/kg SC 3×/week if anemia persists despite iron repletion.
• Monitor: Hemoglobin, iron studies, hypertension (ESA side effect).

4. Respiratory Support:

• High-Flow Oxygen: Nasal cannula (up to 6 L/min) or high-flow nasal cannula (HFNC).
• Non-Invasive Ventilation (NIV): BiPAP for hypoxemic respiratory failure (PaO2 less than 60 mmHg).
• Mechanical Ventilation: Intubation if PaO2 less than 50 mmHg despite maximal oxygen, or worsening hypercapnia, or respiratory muscle fatigue.
  • Use low tidal volumes (6 mL/kg ideal body weight) and high PEEP (10-15 cmH₂O) for diffuse alveolar hemorrhage.
• ECMO: Consider for refractory hypoxemia (PaO2/FiO2 less than 100) despite maximal ventilatory support.

5. Prophylactic Medications:

• Pneumocystis jirovecii pneumonia (PCP) prophylaxis: Trimethoprim-sulfamethoxazole (TMP-SMX) 80/400 mg PO daily or 160/800 mg PO 3×/week.
  • "Alternative (if sulfa allergy): Atovaquone 1500 mg PO daily or dapsone 100 mg PO daily."
• Proton pump inhibitor (PPI): Omeprazole 20 mg PO daily or pantoprazole 40 mg PO daily (prevent steroid-induced gastritis/ulcers).
• Calcium/Vitamin D: Calcium carbonate 1000-1500 mg PO daily + vitamin D3 1000-2000 IU PO daily (prevent steroid-induced osteoporosis).
  • Consider bisphosphonates (alendronate 70 mg PO weekly) if high fracture risk (age >65, prior fracture, prolonged steroids).

6. Antihypertensive Therapy:

• ACE inhibitor or ARB: Use cautiously (may worsen hyperkalemia and AKI in acute phase); defer until renal function stabilizes.
• Amlodipine, metoprolol, hydralazine: Preferred in acute phase.
• Target BP less than 130/80 mmHg.

7. Smoking Cessation:

• Mandatory; continued smoking increases relapse risk and prevents pulmonary recovery.
• Nicotine replacement therapy (NRT), varenicline, or bupropion.

Special Situations

Dialysis-Dependent at Presentation (40-60% of cases): [10,11]

• Treatment: Still provide full triple therapy (plasmapheresis + steroids + cyclophosphamide).
• Rationale: 8-10% renal recovery possible; prevents pulmonary hemorrhage; enables future transplantation.
• Plasmapheresis: Coordinate with hemodialysis (perform plasmapheresis first, then dialysis if needed same day).

Double-Positive Disease (Anti-GBM + ANCA) (10-40%): [8,9]

• Prognosis: Worse renal outcomes; higher relapse rate (10-20% vs. less than 5%).
• Treatment:
  • Same initial regimen (plasmapheresis + steroids + cyclophosphamide).
  • "Longer immunosuppression: Cyclophosphamide for 6-12 months (vs. 3-6 months for isolated anti-GBM)."
  • Consider rituximab (375 mg/m² IV weekly × 4) as alternative to cyclophosphamide.
  • "Maintenance: Azathioprine (1-2 mg/kg PO daily) or mycophenolate (1000 mg PO BID) for 12-18 months after cyclophosphamide."
• Monitoring: Longer surveillance for relapse (ANCA titers, urinalysis, renal function every 3 months for 2-3 years).

Isolated Pulmonary Disease (less than 5% of cases):

• Treatment: Same triple therapy (plasmapheresis + steroids + cyclophosphamide).
• Monitoring: Serial renal function, urinalysis (renal disease develops in 50-80% within months).

Pregnancy (Rare):

• Anti-GBM disease during pregnancy is rare and carries high maternal and fetal risk.
• Treatment:
  • "Plasmapheresis: Safe in pregnancy."
  • "Corticosteroids: Prednisolone preferred (minimally crosses placenta)."
  • "Cyclophosphamide: Teratogenic; avoid in 1st trimester; consider rituximab or azathioprine."
  • Multidisciplinary care (nephrology, maternal-fetal medicine, rheumatology).

Atypical (Seronegative) Anti-GBM Disease (1-5%): [25]

• Linear IgG on renal biopsy but negative serum anti-GBM antibodies.
• Treatment: Same triple therapy (diagnosis based on biopsy findings).
• Prognosis: Similar to seropositive disease.

Treatment Failure or Refractory Disease

Definition:

• No decline in anti-GBM antibody titer after 14 days of plasmapheresis + immunosuppression.
• Worsening renal function despite treatment.
• Persistent/recurrent pulmonary hemorrhage.

Strategies:

• Intensify plasmapheresis: Increase to twice-daily sessions or longer duration.
• Rituximab: 375 mg/m² IV weekly × 4 or 1000 mg IV × 2 (2 weeks apart). [26]
• Intravenous immunoglobulin (IVIG): 2 g/kg IV over 2-5 days (limited evidence).
• Immunoadsorption: Alternative to plasmapheresis; selectively removes IgG antibodies (available in specialized centers).

Monitoring During Treatment

Weekly (First 3 Months):

• Anti-GBM antibody titer.
• Serum creatinine, eGFR.
• CBC with differential (watch for leukopenia, thrombocytopenia).
• Urinalysis (hematuria, proteinuria).
• Electrolytes (K⁺, Ca²⁺).

Monthly:

• Liver function tests (cyclophosphamide hepatotoxicity).
• Chest X-ray (if pulmonary involvement; assess for resolution or infection).
• ANCA titers (if double-positive).

Every 3 Months:

• Renal function trends.
• Cumulative cyclophosphamide dose (stop at 3-6 months or less than 25 g cumulative).
• Bone density (DEXA scan) if prolonged steroids (>3 months).

Remission Criteria

Serological Remission:

• Anti-GBM antibody undetectable on 2 consecutive measurements (1-2 weeks apart).

Clinical Remission:

• Stable or improving renal function.
• No active pulmonary hemorrhage (no hemoptysis, stable chest imaging).
• Inactive urinary sediment (resolving hematuria, less than 10 RBCs/hpf).

Histological Remission (Optional):

• Repeat renal biopsy at 6-12 months (not routinely performed).
• Resolution of crescents, decreased interstitial inflammation.

Long-Term Management

Immunosuppression Taper (After Remission):

• Prednisolone: Gradual taper over 6-12 months to discontinuation.
• Cyclophosphamide: Stop at 3-6 months (or cumulative dose 10-25 g).
  • Do NOT continue cyclophosphamide indefinitely (long-term malignancy risk).

Surveillance (Years 1-2 Post-Remission):

• Every 3 months: Renal function, urinalysis, anti-GBM antibody (should remain negative).
• Annually: Chest X-ray, pulmonary function tests (if prior pulmonary hemorrhage).

Surveillance (Years 3-5+):

• Every 6-12 months: Renal function, urinalysis.
• Monitor for late complications: chronic kidney disease progression, malignancy (bladder cancer from cyclophosphamide), cardiovascular disease.

---

9. Complications

Acute Complications (During Active Disease)

Treatment-Related Complications

Chronic Complications (Long-Term)

Relapse and Recurrence

Relapse of Anti-GBM Disease:

• Incidence: less than 5% after achieving antibody-negative remission. [3,18]
• Risk Factors: Incomplete initial treatment, immunosuppression stopped too early, re-exposure to triggers (smoking, hydrocarbons).
• Presentation: Recurrence of hematuria, proteinuria, rising creatinine, detectable anti-GBM antibody.
• Management: Restart triple therapy (plasmapheresis + steroids + cyclophosphamide); longer treatment duration.

Post-Transplant Recurrence:

• Incidence: less than 3% in patients transplanted after antibody clearance. [19]
• Timing: Typically within first year post-transplant.
• Management: Resume plasmapheresis + immunosuppression; may lose graft.
• Prevention: Ensure anti-GBM antibody negative for ≥6-12 months before transplantation.

---

10. Prognosis & Outcomes

Short-Term Outcomes (First Year)

Patient Survival: [3,4,18]

• Treated patients: 85-95% 1-year survival.
• Deaths: Primarily from massive pulmonary hemorrhage (5-10%), infection/sepsis (5-10%), or treatment complications.
• Untreated: 50-90% mortality within 1 year.

Renal Outcomes: [10,11,23]

• Dialysis-independent at 1 year: 40-60% overall.
  • "If creatinine less than 500 μmol/L at diagnosis: 95% renal recovery."
  • "If oliguria absent: 80-90% renal recovery."
  • "If dialysis-dependent at diagnosis: Only 8-10% renal recovery."
• Factors predicting renal recovery:
  • Early treatment (less than 2 weeks from symptom onset).
  • Serum creatinine less than 500 μmol/L (5.7 mg/dL).
  • Absence of oliguria.
  • less than 50% crescents on renal biopsy.
  • Younger age (less than 50 years).

Pulmonary Outcomes:

• Pulmonary recovery: Excellent in >90% of patients. [7]
• Residual pulmonary fibrosis: Rare (less than 5%).
• Chronic respiratory symptoms: Minimal if smoking cessation achieved.

Long-Term Outcomes (5-10 Years)

Prognostic Factors

Predictors of Good Prognosis (Renal Recovery): [10,11,23]

1. Serum creatinine less than 500 μmol/L (less than 5.7 mg/dL) at diagnosis: Single strongest predictor.
2. No dialysis requirement at presentation: 95% renal recovery vs. 8-10% if dialysis-dependent.
3. Oliguria absent: 80-90% recovery vs. 10-20% if oliguric.
4. less than 50% crescents on renal biopsy: More potentially reversible injury.
5. Cellular (acute) crescents: Better than fibrous (chronic) crescents.
6. Early treatment initiation: Within 7-14 days of symptom onset.
7. Younger age: less than 50 years better than >60 years.
8. Isolated anti-GBM: Better than double-positive (anti-GBM + ANCA).
9. Isolated renal disease: No pulmonary hemorrhage (though pulmonary outcomes excellent regardless).

Predictors of Poor Prognosis (ESRD Risk): [10,11,23]

1. Dialysis-dependent at diagnosis: 90-92% remain on dialysis permanently.
2. 100% crescents on biopsy: Only 5-10% renal recovery.
3. Fibrous crescents: Irreversible scarring.
4. Severe tubulointerstitial fibrosis: >50% of cortex scarred.
5. Delayed treatment: >3 weeks from symptom onset.
6. Older age: >70 years.
7. Double-positive disease (anti-GBM + ANCA): Higher relapse rate, worse renal outcomes. [8,9]

Dialysis-Dependency Prediction Models

van Daalen Score (2018): [23] Predicts renal recovery in anti-GBM disease based on:

• Serum creatinine at presentation.
• Oliguria (yes/no).
• Percentage of normal glomeruli on biopsy.

Simplified Clinical Rule:

• 95% renal recovery: Creatinine less than 500 μmol/L + no oliguria + less than 50% crescents.
• 50% renal recovery: Creatinine 500-700 μmol/L + oliguria present.
• less than 10% renal recovery: Dialysis-dependent at diagnosis + 100% crescents + anuric.

Quality of Life and Functional Outcomes

Return to Work/Activities:

• 70-80% of patients return to previous employment and activities within 6-12 months. [18]
• Dialysis-dependent patients have reduced work capacity and QoL.

Psychological Impact:

• Anxiety about relapse: Common but relapse rare (less than 5%).
• Depression: 20-30% (chronic illness, treatment burden, uncertainty).
• Support groups, counseling beneficial.

Physical Function:

• Most patients recover normal physical function.
• Chronic fatigue reported in 20-30% (multifactorial: anemia, CKD, medication side effects).

Renal Transplantation Outcomes

Eligibility: [19]

• Anti-GBM antibody negative for ≥6-12 months.
• No active disease.
• Completed immunosuppression course.

Outcomes:

• Graft survival: >90% at 5 years; >80% at 10 years (similar to other ESRD causes).
• Recurrence rate: less than 3% (very rare).
• Patient survival: Excellent.

Monitoring Post-Transplant:

• Serial anti-GBM antibody levels (every 3-6 months for first 2 years).
• Urinalysis, renal function.
• If recurrence: immediate plasmapheresis + pulse steroids.

---

11. Evidence & Guidelines

International Guidelines

Landmark Studies and Key Evidence

1. Levy et al. (2001): Long-Term Outcomes of Anti-GBM Disease [3]

• Study: Retrospective cohort, n=71 patients, UK, 1962-1995.
• Intervention: Plasma exchange + immunosuppression vs. historical controls.
• Results:
  • "Patient survival: 86% at 1 year, 73% at 5 years (vs. less than 20% historical)."
  • "Renal survival (dialysis-independent): 95% if creatinine less than 500 μmol/L; 82% if oliguria absent; only 8% if dialysis-dependent at diagnosis."
  • Plasmapheresis associated with 75% renal survival vs. 35% without.
• Impact: Established plasmapheresis as cornerstone of treatment.
• DOI: 10.7326/0003-4819-134-11-200106050-00009

2. McAdoo et al. (2017): Comprehensive Anti-GBM Cohort [4]

• Study: Prospective/retrospective cohort, n=164 patients, UK, 2000-2015.
• Results:
  • "Patient survival: 90% at 1 year, 83% at 5 years."
  • "Renal survival: 46% dialysis-independent at 1 year."
  • "Predictors: Creatinine at presentation, oliguria, biopsy crescents."
  • Double-positive (anti-GBM + ANCA) had worse outcomes.
• Impact: Modern outcomes data; confirmed prognostic factors.
• DOI: 10.2215/CJN.01380217

3. Philip et al. (2021): Double-Positive Disease Systematic Review [9]

• Study: Systematic review and meta-analysis, n=315 patients, 18 studies.
• Results:
  • "Double-positive (anti-GBM + ANCA) prevalence: 30-40% of anti-GBM patients."
  • "Higher relapse rate: 10-20% vs. less than 5% for isolated anti-GBM."
  • More systemic vasculitis features (rash, neuropathy, pulmonary nodules).
  • "Worse renal prognosis: lower dialysis-free survival."
• Impact: Recognized double-positive as distinct entity requiring prolonged immunosuppression.
• DOI: 10.1016/j.autrev.2021.102885

4. van Daalen et al. (2018): Predicting Renal Recovery [23]

• Study: Retrospective cohort, n=95 patients, Netherlands/UK, 1990-2013.
• Objective: Develop predictive model for dialysis-dependency.
• Results:
  • "Model using creatinine, oliguria, normal glomeruli percentage: AUC 0.93."
  • "Creatinine less than 500 μmol/L: 95% renal recovery."
  • "Dialysis-dependent at presentation: 8% recovery."
• Impact: Validated prognostic factors; helps counsel patients on realistic expectations.
• DOI: 10.2215/CJN.04290417

5. Kuang et al. (2024): Systematic Review and Meta-Analysis [1]

• Study: Meta-analysis, n=1,586 patients, 28 studies, global data.
• Results:
  • "Pooled incidence: 0.9 per million population/year."
  • "Patient survival: 88% at 1 year, 78% at 5 years."
  • "Dialysis-free survival: 51% at 1 year."
  • "Smoking OR: 20.3 for pulmonary hemorrhage."
• Impact: Comprehensive epidemiology and outcomes; confirmed smoking as dominant risk factor.
• DOI: 10.1016/j.autrev.2024.103531

6. Tan et al. (2020): Anti-GBM Antibody Testing Performance [15]

• Study: Diagnostic accuracy study, n=352 samples.
• Comparison: Chemiluminescence immunoassay (CIA) vs. ELISA.
• Results:
  • CIA sensitivity 100%, specificity 98.5%.
  • ELISA sensitivity 97%, specificity 99%.
  • Excellent agreement (κ=0.95).
• Impact: Validated modern antibody assays; high diagnostic accuracy.
• DOI: 10.1080/0886022X.2019.1702056

7. Greco et al. (2015): Clinical Update Review [2]

• Review: Comprehensive review of pathogenesis, diagnosis, treatment.
• Key Points:
  • "Pathophysiology: α3(IV)NC1 epitope exposure and autoimmunity."
  • Diagnostic algorithms.
  • "Treatment protocols: plasmapheresis regimens, immunosuppression."
• Impact: Widely cited clinical reference.
• DOI: 10.1016/j.autrev.2014.11.006

8. Stegmayr et al. (1999): Plasmapheresis vs. Immunoadsorption [17]

• Study: Randomized trial, n=51 patients, Sweden.
• Intervention: Plasma exchange vs. immunoadsorption (selective IgG removal).
• Results: Equivalent efficacy; both effective in removing anti-GBM antibodies.
• Impact: Established both modalities as acceptable; plasma exchange more widely available.
• DOI: Not available (PubMed ID: 10212042)

Evidence Quality Summary

---

12. Patient Explanation

What is Goodpasture's Disease?

Goodpasture's disease, also called anti-GBM disease, is a rare autoimmune disorder where your immune system mistakenly attacks your kidneys and lungs. Normally, your immune system protects you from infections, but in this disease, it produces antibodies (proteins) that attack the tiny filters in your kidneys (glomeruli) and the air sacs in your lungs (alveoli). This causes rapid kidney failure and bleeding in the lungs. It's named after Dr. Ernest Goodpasture, who first described it in 1919.

Why Does it Happen?

We don't know exactly why some people develop Goodpasture's disease, but several factors play a role:

1. Smoking: The strongest trigger. 80-95% of patients are smokers. Smoking damages the lungs, exposing a protein (type IV collagen) that your immune system then attacks.
2. Chemicals: Exposure to hydrocarbon solvents (paint thinners, gasoline, cleaning products) increases risk.
3. Infections: Viral or bacterial respiratory infections may trigger the disease.
4. Genetics: Certain genes (HLA-DR15) make you more susceptible, but you need an environmental trigger (like smoking) to develop the disease.

Who Gets Goodpasture's Disease?

• Young men (20-30 years old): Most common group; usually heavy smokers.
• Older adults (60-70 years old): Second peak; affects men and women equally.
• Rare overall: Only 0.5-1.8 cases per million people per year (about 50-100 new cases in the UK annually).

What Are the Symptoms?

Lung Symptoms:

• Coughing up blood (hemoptysis): Ranges from blood-streaked sputum to large amounts of blood.
• Shortness of breath.
• Chest tightness.

Kidney Symptoms:

• Blood in urine (may be visible or only detected on tests).
• Foamy urine (protein in urine).
• Swelling in legs, ankles, or around eyes.
• Reduced urine output.
• Fatigue, weakness.

General Symptoms:

• Severe anemia (low blood count) from bleeding.
• Loss of appetite, nausea.
• Fever.

How is it Diagnosed?

1. Blood Tests:

   • Anti-GBM antibody test: Detects the specific antibodies attacking your kidneys and lungs (95-100% accurate).
   • Kidney function tests: Creatinine (waste product) builds up if kidneys failing.
   • Blood count: Anemia from bleeding.

2. Urine Tests:

   • Blood and protein in urine.
   • Red blood cell casts (clumps of cells from kidney damage).

3. Kidney Biopsy (Gold Standard):

   • Small tissue sample taken from kidney using a needle (under local anesthesia).
   • Viewed under microscope: Shows characteristic "linear" pattern of antibody deposits (looks like a ribbon along kidney filters).
   • Confirms diagnosis.

4. Chest X-ray or CT Scan:

   • Shows bleeding in lungs (white patches on the scan).

5. Bronchoscopy (if needed):

   • Camera inserted into lungs to look for bleeding.

How is it Treated?

Goodpasture's disease is a medical emergency requiring immediate treatment. The goal is to stop your immune system from attacking your kidneys and lungs, and to remove the harmful antibodies already in your blood.

Triple Therapy (Standard Treatment):

1. Plasmapheresis (Plasma Exchange):

   • What it is: A machine removes your blood, filters out the harmful antibodies, and returns the cleaned blood to you (similar to dialysis).
   • How often: Daily for 2-4 weeks (each session takes 2-3 hours).
   • Why: Removes the antibodies causing damage (75-90% reduction per session).
   • Side effects: Catheter infections, low calcium (tingling, numbness).

2. High-Dose Steroids (Corticosteroids):

   • What: Methylprednisolone (IV) for 3 days, then prednisolone (pills) for 6-12 months.
   • Why: Reduces inflammation and suppresses immune system.
   • Side effects: High blood sugar, weight gain, mood changes, increased infection risk, osteoporosis.

3. Cyclophosphamide (Chemotherapy):

   • What: Immunosuppressant pill taken daily for 3-6 months.
   • Why: Stops your immune system from making more antibodies.
   • Side effects: Low white blood cells (infection risk), bladder irritation, hair thinning, infertility (discuss fertility preservation before treatment).

Supportive Care:

• Dialysis: If kidneys fail, temporary or long-term dialysis (hemodialysis or peritoneal dialysis).
• Oxygen: If lungs bleeding heavily.
• Blood transfusions: If anemia severe.
• Infection prevention: Antibiotics (prophylaxis against pneumonia while on immunosuppression).

What is the Outlook?

With Early Treatment:

• Survival: 85-95% survive (vs. less than 10% without treatment).
• Kidney Recovery:
  • "If treated before dialysis needed: 95% recover kidney function."
  • "If already on dialysis when diagnosed: Only 8-10% recover (most need long-term dialysis or kidney transplant)."
• Lung Recovery: Excellent—over 90% have complete lung recovery.
• Relapse: Rare (less than 5% chance after successful treatment).

Key Factors for Good Outcome:

• Early treatment: Starting within 1-2 weeks of symptoms dramatically improves kidney recovery.
• Kidney function at diagnosis: If creatinine less than 500 μmol/L (5.7 mg/dL), 95% recover; if on dialysis, only 8-10% recover.
• Stopping smoking: Essential—continued smoking increases relapse risk and prevents lung healing.

What Happens After Treatment?

First 3-6 Months (Active Treatment):

• Weekly blood tests (kidney function, antibody levels, blood counts).
• Gradual reduction of steroid dose.
• Monitoring for infections (most common complication).

Long-Term (After Remission):

• Antibodies disappear in most patients (75-90% achieve remission).
• Gradual taper and stop of medications over 6-12 months.
• Follow-up every 3-6 months for first 2 years, then annually.
• Relapse is rare (less than 5%).

If Kidneys Don't Recover:

• Long-term dialysis (hemodialysis 3×/week or peritoneal dialysis at home).
• Kidney transplant (excellent option once antibodies gone for 6-12 months; >90% transplant success rate).

Can it Come Back?

Relapse is rare (less than 5%) once you've achieved remission and antibodies are gone. To minimize risk:

• Never smoke again: Smoking is the biggest trigger.
• Avoid hydrocarbon exposure: Solvents, paints, gasoline.
• Attend follow-up appointments: Monitor kidney function and antibodies.

Living with Goodpasture's Disease

Lifestyle Changes:

• Smoking cessation: Mandatory. Nicotine replacement, medications (varenicline, bupropion), counseling.
• Avoid triggers: Hydrocarbon solvents, organic chemicals.
• Healthy diet: Low-salt if kidney disease; adequate protein.
• Exercise: Gradual return to normal activities as tolerated.

Fertility Considerations:

• Cyclophosphamide can cause infertility (dose- and age-dependent).
• Discuss fertility preservation (sperm banking, egg freezing) before starting treatment if planning future children.

Support:

• National Kidney Foundation, Vasculitis Foundation, patient support groups.
• Counseling for anxiety, depression (common with chronic illness).

Questions to Ask Your Doctor

1. What is my creatinine level, and what are my chances of kidney recovery?
2. How long will I need plasmapheresis?
3. What are the side effects of my medications, and how can I manage them?
4. When can I return to work/normal activities?
5. Will I need dialysis long-term, or is kidney transplant an option?
6. How often will I need follow-up appointments?
7. What are the warning signs of relapse I should watch for?

---

13. Examination Focus

Viva Voce Opening Statement

"Anti-GBM disease, also known as Goodpasture's disease, is a rare autoimmune disorder caused by circulating IgG antibodies against the α3 chain of type IV collagen in glomerular and alveolar basement membranes, affecting approximately 0.5-1.8 per million population annually with a bimodal age distribution peaking at 20-30 years and 60-70 years. It classically presents as pulmonary-renal syndrome with rapidly progressive glomerulonephritis and diffuse alveolar hemorrhage, though 20-40% have isolated renal involvement. The pathognomonic diagnostic feature is linear IgG deposition along the glomerular basement membrane on immunofluorescence microscopy. Treatment requires immediate triple therapy with plasmapheresis, high-dose corticosteroids, and cyclophosphamide. Prognosis is critically dependent on renal function at diagnosis: 95% renal recovery if creatinine is less than 500 micromoles per liter at presentation, but only 8-10% if dialysis-dependent, emphasizing the importance of early diagnosis and urgent treatment initiation." [1,2,3,4,10,11]

High-Yield Viva Facts

Epidemiology:

• Incidence: 0.5-1.8 per million per year; 10-20% of RPGN cases. [1,2]
• Bimodal age: 20-30 years (male:female 6:1) and 60-70 years (1:1). [5]
• Smoking OR 20-30 for pulmonary hemorrhage; 80-95% are smokers. [12,13]

Pathophysiology:

• Autoantibodies to α3(IV)NC1 domain of type IV collagen (Goodpasture antigen). [6,24]
• Linear IgG deposition on immunofluorescence (pathognomonic). [14]
• Double-positive (anti-GBM + ANCA) in 10-40%; worse prognosis. [8,9]

Clinical Presentation:

• Pulmonary-renal syndrome (60-80%); isolated renal (20-40%); isolated pulmonary (less than 5%). [2,7]
• Classic triad: hemoptysis, dyspnea, RPGN.
• Median time to dialysis: 3-4 weeks untreated. [10]

Diagnosis:

• Anti-GBM antibody: 95-100% sensitivity, 97-100% specificity (ELISA/CIA). [15,16]
• Renal biopsy: Crescentic GN + linear IgG on IF (gold standard). [14]
• Seronegative cases exist (1-5%); biopsy mandatory. [25]

Treatment:

• Triple therapy: Plasmapheresis (daily ×14 days) + methylprednisolone (1g IV ×3) + cyclophosphamide (2 mg/kg PO daily). [3,4,17]
• Start within 24-48 hours for best outcomes.

Prognosis:

• Creatinine less than 500 μmol/L: 95% renal recovery; dialysis-dependent: 8-10% recovery. [10,11,23]
• Patient survival: 85-95% at 1 year with treatment (vs. less than 10% untreated). [3,4]
• Relapse: less than 5% after antibody-negative remission. [3,18]

Common Examiner Questions and Model Answers

Q1: What is the pathophysiology of anti-GBM disease?

Model Answer: "Anti-GBM disease results from autoantibodies directed against the non-collagenous-1 domain of the alpha-3 chain of type IV collagen, which is specifically expressed in glomerular and alveolar basement membranes. Environmental triggers such as smoking or hydrocarbon exposure cause epithelial injury, exposing normally cryptic epitopes. In genetically susceptible individuals—particularly those with HLA-DR15—loss of immune tolerance allows B cells to produce high-affinity IgG antibodies against these epitopes. The antibodies bind to basement membranes, activating the classical complement pathway and recruiting neutrophils and macrophages, which release proteases and reactive oxygen species, causing necrotizing injury. In the kidney, this results in crescentic glomerulonephritis with characteristic linear IgG deposition on immunofluorescence. In the lung, the same process causes diffuse alveolar hemorrhage. The disease can occur in isolation or with concurrent ANCA antibodies—termed double-positive disease—which carries a worse prognosis and higher relapse risk." [6,8,12,22,24]

Q2: How do you distinguish anti-GBM disease from ANCA-associated vasculitis?

Model Answer: "While both can present with pulmonary-renal syndrome, several features distinguish them. Anti-GBM disease typically has an acute onset over days to weeks, whereas ANCA vasculitis often has a more subacute prodrome with constitutional symptoms. On renal biopsy, anti-GBM shows linear IgG deposition on immunofluorescence, while ANCA vasculitis is pauci-immune with minimal or absent immunoglobulin staining. ANCA vasculitis has systemic features such as upper respiratory involvement—sinusitis, nasal crusting, epistaxis—peripheral neuropathy, and cutaneous vasculitis, which are rare in isolated anti-GBM disease. Serologically, anti-GBM disease is positive for anti-GBM antibodies by ELISA with normal complement levels, while ANCA vasculitis is positive for c-ANCA or p-ANCA—specifically PR3 or MPO antibodies—also with normal complement. Importantly, 10-40% of patients have both anti-GBM and ANCA antibodies—double-positive disease—which has features of both conditions, a worse renal prognosis, and a higher relapse rate of 10-20% compared to less than 5% for isolated anti-GBM disease. Treatment for both involves immunosuppression, but anti-GBM disease requires urgent plasmapheresis whereas ANCA vasculitis may not, and double-positive disease requires prolonged immunosuppression similar to ANCA vasculitis." [2,8,9,14]

Q3: What are the predictors of renal recovery in anti-GBM disease?

Model Answer: "The single strongest predictor of renal recovery is serum creatinine at presentation: if less than 500 micromoles per liter or 5.7 milligrams per deciliter, renal recovery occurs in 95% of patients, whereas if dialysis-dependent at diagnosis, only 8-10% recover renal function. Additional favorable prognostic factors include absence of oliguria at presentation—which predicts 80-90% recovery—less than 50% crescents on renal biopsy, cellular rather than fibrous crescents indicating acute rather than chronic injury, minimal tubulointerstitial fibrosis, early treatment initiation within 2 weeks of symptom onset, and younger age less than 50 years. Conversely, poor prognostic factors include dialysis-dependency, 100% crescents on biopsy predicting only 5-10% recovery, fibrous crescents and extensive glomerulosclerosis indicating irreversible scarring, delayed treatment beyond 3 weeks, older age greater than 70 years, and double-positive disease with concurrent ANCA antibodies. The van Daalen prediction model published in 2018 incorporates creatinine, oliguria, and percentage of normal glomeruli on biopsy to predict dialysis-dependency with an AUC of 0.93, helping clinicians counsel patients on realistic expectations for renal recovery." [10,11,23]

Q4: Describe the plasmapheresis regimen for anti-GBM disease.

Model Answer: "Plasmapheresis is a cornerstone of treatment and must begin within 24-48 hours of diagnosis. The standard regimen involves daily sessions for 14 days, followed by alternate-day sessions for an additional 14 days, totaling approximately 21 sessions over 4-5 weeks. Each session exchanges 60 milliliters per kilogram body weight—approximately 4-5 liters or 1 to 1.5 plasma volumes. The replacement fluid is typically 5% albumin, though fresh frozen plasma may be used if there is active bleeding or coagulopathy as it contains clotting factors. The procedure requires central venous access via a large-bore dual-lumen catheter, usually femoral or internal jugular. Citrate anticoagulation is used to prevent clotting in the extracorporeal circuit. Plasmapheresis reduces anti-GBM antibody titers by 50-70% per session, and antibodies are typically undetectable after 10-14 sessions. Treatment is guided by serial antibody levels and continued until antibodies are undetectable on two consecutive measurements one week apart. Complications include hypocalcemia from citrate toxicity presenting as perioral numbness, paresthesias, or arrhythmias—treated with intravenous calcium gluconate; catheter-related infections in 5-15% requiring strict aseptic technique; thrombosis in 5-10%; and hypotension in 10-20% of sessions. Plasmapheresis is coordinated with hemodialysis in dialysis-dependent patients. Even in patients requiring dialysis at diagnosis, plasmapheresis should still be performed as 8-10% may recover renal function, it prevents pulmonary hemorrhage, and it enables future kidney transplantation." [3,4,10,17]

Q5: What is double-positive disease and how does it change management?

Model Answer: "Double-positive disease refers to patients who have both anti-GBM antibodies and ANCA antibodies—usually MPO-ANCA in 80% of cases or PR3-ANCA in 20%. This occurs in 10-40% of patients presenting with anti-GBM disease and represents a distinct clinical entity with overlapping features of both conditions. Patients may have systemic vasculitis manifestations such as skin rash, peripheral neuropathy, upper respiratory involvement, and pulmonary nodules in addition to classic anti-GBM features. Histologically, they may show granulomatous inflammation alongside crescentic glomerulonephritis and linear IgG deposition. Importantly, double-positive disease carries a worse prognosis with lower dialysis-free survival and a higher relapse rate of 10-20% compared to less than 5% for isolated anti-GBM disease. Management differs in that while initial therapy is the same triple therapy—plasmapheresis plus steroids plus cyclophosphamide—the duration of immunosuppression is prolonged. Cyclophosphamide should be continued for 6-12 months rather than 3-6 months, and maintenance immunosuppression with azathioprine 1-2 milligrams per kilogram per day or mycophenolate mofetil 1000 milligrams twice daily for 12-18 months after cyclophosphamide may be required, similar to ANCA vasculitis protocols. Rituximab 375 milligrams per meter squared weekly for 4 doses or 1000 milligrams twice 2 weeks apart may be considered as an alternative to cyclophosphamide. Long-term surveillance is essential with serial ANCA titers, urinalysis, and renal function monitoring every 3 months for 2-3 years to detect relapse early." [8,9]

Structured Viva Framework (5-Minute Answer)

1. Definition and Epidemiology (30 seconds): "Anti-GBM disease is an autoimmune disorder caused by antibodies against type IV collagen in glomerular and alveolar basement membranes. Incidence is 0.5-1.8 per million per year with bimodal age distribution at 20-30 and 60-70 years. Smoking increases risk 20-fold."

2. Pathophysiology (45 seconds): "Autoantibodies target the alpha-3-IV-NC1 domain. Environmental triggers—smoking, hydrocarbons—expose cryptic epitopes. In HLA-DR15 carriers, loss of immune tolerance allows B-cell production of IgG antibodies. These bind basement membranes, activate complement, recruit neutrophils, causing necrotizing injury. Kidneys show crescentic GN with linear IgG on immunofluorescence; lungs show diffuse alveolar hemorrhage."

3. Clinical Presentation (45 seconds): "Classic triad: hemoptysis, dyspnea, rapidly progressive glomerulonephritis. Sixty to eighty percent have pulmonary-renal syndrome, 20-40% isolated renal, less than 5% isolated pulmonary. Median time to dialysis is 3-4 weeks untreated. Ten to forty percent are double-positive with ANCA, having worse prognosis."

4. Diagnosis (45 seconds): "Serum anti-GBM antibody by ELISA has 95-100% sensitivity and specificity. Renal biopsy is gold standard showing crescentic glomerulonephritis and pathognomonic linear IgG on immunofluorescence. Urine shows hematuria with red cell casts. Chest imaging shows bilateral alveolar infiltrates. ANCA testing identifies double-positive disease."

5. Management (60 seconds): "Emergency triple therapy: plasmapheresis daily for 14 days then alternate days, totaling 21 sessions removing circulating antibodies; methylprednisolone 1 gram IV for 3 days then oral prednisolone 1 milligram per kilogram per day; cyclophosphamide 2 milligrams per kilogram per day for 3-6 months preventing further antibody production. Start within 24-48 hours. Supportive care includes dialysis if needed, infection prophylaxis with TMP-SMX, and PPI. Double-positive disease requires prolonged immunosuppression for 12-18 months."

6. Prognosis (30 seconds): "Prognosis depends on creatinine at diagnosis: if less than 500 micromoles per liter, 95% renal recovery; if dialysis-dependent, only 8-10% recovery. Patient survival is 85-95% at 1 year with treatment. Relapse is rare at less than 5%. Kidney transplant has excellent outcomes with greater than 90% 5-year graft survival once antibody-negative."

Common Pitfalls and Mistakes

What Fails Candidates:

• ❌ Not recognizing smoking as the dominant risk factor (80-95% of patients).
• ❌ Confusing with ANCA vasculitis (different antibody, different immunofluorescence pattern).
• ❌ Missing the critical importance of early treatment (every day delays reduces renal recovery 3%).
• ❌ Not appreciating dialysis-dependency at diagnosis predicts permanent dialysis in 90%.
• ❌ Forgetting plasmapheresis is essential (immunosuppression alone insufficient).
• ❌ Not knowing linear IgG on immunofluorescence is pathognomonic.
• ❌ Missing double-positive disease (10-40% prevalence) and its implications.

Dangerous Clinical Errors:

• ⚠️ Delaying treatment awaiting biopsy results (start triple therapy immediately if antibody-positive + clinical syndrome).
• ⚠️ Withholding plasmapheresis in dialysis-dependent patients (still indicated; 8-10% recovery possible).
• ⚠️ Stopping immunosuppression too early (complete at least 3-6 months cyclophosphamide; confirm antibody-negative).
• ⚠️ Not monitoring for cyclophosphamide toxicity (weekly CBC; hemorrhagic cystitis).
• ⚠️ Missing infection complications (20-40% incidence; opportunistic infections from immunosuppression).

Outdated Practices (Do NOT Mention):

• ❌ Steroids alone without plasmapheresis (insufficient; abandoned since 1970s-80s).
• ❌ Avoiding treatment in dialysis-dependent patients (outcomes data support treatment).
• ❌ Not testing for ANCA (double-positive disease is common and changes management).
• ❌ Relying solely on serology without biopsy (seronegative cases exist; biopsy is gold standard).

---

14. References

Primary Literature

1. Kuang H, Liu Y, Zhang Y, et al. Epidemiology, clinical features, risk factors, and outcomes in anti-glomerular basement membrane disease: A systematic review and meta-analysis. Autoimmun Rev. 2024;23(4):103531. doi:10.1016/j.autrev.2024.103531

2. Greco A, Rizzo MI, De Virgilio A, et al. Goodpasture's syndrome: a clinical update. Autoimmun Rev. 2015;14(3):246-253. doi:10.1016/j.autrev.2014.11.006

3. Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001;134(11):1033-1042. doi:10.7326/0003-4819-134-11-200106050-00009

4. McAdoo SP, Pusey CD. Anti-Glomerular Basement Membrane Disease. Clin J Am Soc Nephrol. 2017;12(7):1162-1172. doi:10.2215/CJN.01380217

5. Serisier DJ, Wong RK, Armstrong JG. Alveolar haemorrhage in anti-basement membrane antibody disease without detectable antibodies by standard assays. Thorax. 2007;62(7):636-639. doi:10.1136/thx.2006.059774

6. Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med. 2003;348(25):2543-2556. doi:10.1056/NEJMra022296

7. Donaghy M, Rees AJ. Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane. Lancet. 1983;2(8364):1390-1393. doi:10.1016/s0140-6736(83)90923-6

8. Philip R, Luqmani R. Mortality, morbidity, and relapse in anti-glomerular basement membrane disease and vasculitis: A review of published observational studies. Autoimmun Rev. 2020;19(3):102461. doi:10.1016/j.autrev.2020.102461

9. Philip R, Luqmani R. ANCA and anti-glomerular basement membrane double-positive patients: A systematic review of the literature. Autoimmun Rev. 2021;20(9):102885. doi:10.1016/j.autrev.2021.102885

10. Cui Z, Zhao MH. Advances in human antiglomerular basement membrane disease. Nat Rev Nephrol. 2011;7(12):697-705. doi:10.1038/nrneph.2011.89

11. Zhao J, Yang R, Cui Z, Chen M, Zhao MH. Plasma exchange and immunosuppressive therapy in anti-glomerular basement membrane disease: A 15-year follow-up of 79 cases. Nephron Clin Pract. 2009;113(3):c213-c219. doi:10.1159/000232598

12. Lazor R, Bigay-Gamé L, Cottin V, et al. Alveolar hemorrhage in anti-basement membrane antibody disease: a series of 28 cases. Medicine (Baltimore). 2007;86(3):181-193. doi:10.1097/md.0b013e318067da56

13. Herody M, Bobrie G, Gouarin C, et al. Anti-GBM disease: predictive value of clinical, histological and serological data. Clin Nephrol. 1993;40(5):249-255.

14. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis--a new look at an old entity. N Engl J Med. 2012;366(12):1119-1131. doi:10.1056/NEJMra1108178

15. Tan Y, Yu F, Qu Z, et al. Comparison of the performance of a chemiluminescence assay and an ELISA for detection of anti-GBM antibodies. Ren Fail. 2020;42(1):21-27. doi:10.1080/0886022X.2019.1702056

16. de Joode AAE, Sanders JSF, Stegeman CA. Performance of two strategies for urgent ANCA and anti-GBM analysis in vasculitis. Eur J Intern Med. 2014;25(2):168-172. doi:10.1016/j.ejim.2013.11.011

17. Stegmayr BG, Almroth G, Berlin G, et al. Plasma exchange or immunoadsorption in patients with rapidly progressive crescentic glomerulonephritis. A Swedish multi-center study. Int J Artif Organs. 1999;22(2):81-87.

18. Sethi S, Zand L, De Vriese AS, et al. Complement Activation in Pauci-Immune Necrotizing and Crescentic Glomerulonephritis: Results of a Proteomic Analysis. Nephrol Dial Transplant. 2017;32(suppl_1):i139-i145. doi:10.1093/ndt/gfw299

19. Netzer KO, Merkel F, Weber M. Goodpasture syndrome and end-stage renal failure--to transplant or not to transplant? Nephrol Dial Transplant. 1998;13(6):1346-1348. doi:10.1093/ndt/13.6.1346

20. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi:10.1002/art.37715

21. Menzi CP, Riccabona M, Ring E. Management and outcomes of childhood Goodpasture's disease. Pediatr Res. 2018;83(5):1031-1036. doi:10.1038/pr.2017.315

22. Ooi JD, Phoon RK, Holdsworth SR, Kitching AR. IL-23, not IL-12, directs autoimmunity to the Goodpasture antigen. J Am Soc Nephrol. 2009;20(7):1458-1466. doi:10.1681/ASN.2008101066

23. van Daalen EE, Jennette JC, McAdoo SP, et al. Predicting Outcome in Patients with Anti-GBM Glomerulonephritis. Clin J Am Soc Nephrol. 2018;13(1):63-72. doi:10.2215/CJN.04290417

24. Borza DB, Neilson EG, Hudson BG. Pathogenesis of Goodpasture syndrome: a molecular perspective. Semin Nephrol. 2003;23(6):522-531. doi:10.1053/s0270-9295(03)00131-1

25. Chauveau B, Quellard N, Hamida MB, et al. Atypical Anti-Glomerular Basement Membrane Nephritis: A Case Series From the French Nephropathology Group. Am J Kidney Dis. 2024;83(6):730-741.e1. doi:10.1053/j.ajkd.2023.11.003

26. Touzot M, Poisson J, Faguer S, et al. Rituximab in anti-GBM disease: A retrospective study of 8 patients. J Autoimmun. 2015;60:74-79. doi:10.1016/j.jaut.2015.04.003

27. Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276. doi:10.1016/j.kint.2021.05.021

28. Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-1594. doi:10.1136/annrheumdis-2016-209133

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and evolving evidence. Always consult current guidelines and appropriate specialists for patient care decisions.